e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Bronchodilator treatment for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of tiotropium in COPD patients with FEV
1
≥ 60% participating in the UPLIFT trial
D. Tashkin, B. Celli, T. Lystig, S. Kesten, M. Decramer (Los Angeles, Boston, Ridgefield, United States Of America; , Belgium)
Source:
Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Session:
Bronchodilator treatment for asthma and COPD
Session type:
Thematic Poster Session
Number:
1186
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Tashkin, B. Celli, T. Lystig, S. Kesten, M. Decramer (Los Angeles, Boston, Ridgefield, United States Of America; , Belgium). Efficacy of tiotropium in COPD patients with FEV
1
≥ 60% participating in the UPLIFT trial. Eur Respir J 2010; 36: Suppl. 54, 1186
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Randomized, double blind, double dummy, placebo-controlled trial designed for comparing the effectiveness of formoterol (Foradil®) Aerolizer® and ipatropium bromide plus nebulized fenoterol (Berodual®) in asthma patients with ages ranging between 5 and 12 years who suffer acute asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Clinical efficacy and patients‘ satisfaction for 100 consequent COPD patients using tiotropium respimat
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation
vs
placebo (pbo) and formoterol (for)
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Association of β
2
-adrenoreceptor genotypes with prevention of COPD exacerbations by tiotropium or salmeterol in the POET-COPD® trial
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPDÔ trial
Source: Annual Congress 2011 - COPD management
Year: 2011
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study
Source: Eur Respir J 2016; 48: 1030-1039
Year: 2016
Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
A randomised double-blind, study to determine the efficacy & safety of a once-daily inhaled β
2
adrenoreceptor agonist, PF-00610355 in asthmatic patients
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Safety of tiotropium in patients with cardiac events in the UPLIFT® trial
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study
versus
placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept